How Can Payers Advance Patient-reported Measures in Oncology?
A newly published study explored patient-reported performance measures in oncology, the barriers to implementation, and actionable recommendations for public and [...]
Achieving Accurate Estimates of Shared Savings from Value-based Healthcare
This article is part of a series focused on calculating shared savings from value-based health care improvement solutions. There is [...]
[Podcast] Bruno Villetelle on Real World Data’s Role in Bringing Medication to Market
In this episode of Real World Talk, join host Emily Di Capua as she discusses the ways in which RWD [...]
[Virtual Summit] How much drug research will we sacrifice to save money?
Tune in to the 2020 STAT Summit On November 18th at 3:45pm ET for a robust discussion on the cost [...]
[Webinar] Putting Artificial Intelligence in R&D
Big Pharma and biotech are increasingly using artificial intelligence in drug discovery. Join a distinguished panel of experts on October [...]
ISPOR Invites Applications For President-Elect or Director
The ISPOR Nominations Committee is now inviting members to nominate themselves or a colleague or to serve as President-Elect or [...]
Value-based Care at Risk
An April survey by the National Association of ACOs showed that more than half the organizations in at-risk models planned [...]
Payers: The New Catalysts of Better Health
As health care delivery is getting more complex, the traditional definition of healthcare is evolving. This shift is necessitating the [...]
Trial Site Networks: Create Positive Change Through A Shift in Perspective
COVID-19 represents a stress test of sorts for our global healthcare system that will hopefully lead to positive changes over [...]
Patient Intelligence and Insights Reports Available from Self Care Catalysts
Patients negotiate a shifting landscape of goals and aspirations. They have to navigate unmet needs, barriers to care, influencers and [...]
Submit Your Abstracts for Virtual ISPOR 2021
Abstract Submissions Are Open for Virtual ISPOR 2021; May 17 – 20: "HEOR: Evolving for Tomorrow's Challenges" Submit under the [...]
Adaptive Trial Designs in Early Oncology
Our understanding of the genetic and molecular mechanisms that lead to cancer have improved greatly over the past decade thanks [...]
Bart Heeg on New Trends in HEOR
In this two-part blog series, Bart Heeg, Vice President HEOR and Founder at Ingress Health (A Cytel company) discusses trends [...]
Draft Scoping Document for the Assessment of Alzheimer’s Disease Posted by ICER
Yesterday the Institute for Clinical and Economic Review (ICER) posted a Draft Scoping Document detailing the planned review of the comparative clinical effectiveness [...]
FDA Approved NDA for KOSELUGO™ (selumetinib)
Recently the FDA approved AstraZeneca’s KOSELUGO™ (selumetinib) for treatment of pediatric patients two years of age and older with neurofibromatosis [...]
Pfizer Seeks Judgment Favoring Proposed Patient-assistance Programs
If Pfizer wins their lawsuit against the U.S. government, Medicare stands to spend much, much more on some drugs. Pfizer [...]
Thomas Wilke Weighs In On Health Economics and Real-World Evidence Studies
In this interview, Thomas Wilke, Principal Scientist at Ingress-Health (a Cytel company), discusses his background and experience in HEOR to [...]
Lessons Learned from COVID-19 Health Preference Research
The COVID-19 pandemic caused a major shift in the lives of many HEOR researchers, especially those conducting health preference research. [...]
Building a More Consumer-Centric Future in the Era of COVID
The urgent need to scale healthcare innovation has been unmasked by the COVID-19 pandemic, making consumerism an essential tenet of [...]
Beyond Real-World Data and COVID-19
Join Casey Ross and other industry leaders as they discuss applications of real-world data in the battle against Covid-19. In [...]
[Podcast] The MM+M Podcast: FDA’s Bakul Patel
Bakul Patel has been leading regulatory and scientific efforts related to digital health devices at the FDA since 2010. Tune [...]
What Does the Rise of Real-World Evidence Mean For Pharma?
The COVID-19 pandemic has highlighted the urgent need for real-world evidence to inform decision making. This month’s issue of ISPOR [...]
Unlocking the Promise of Real-World Evidence
At present, researchers have an abundance of real-world data. Although these data have been primarily used for safety surveillance, they [...]
Updates From the Real-World Evidence Transparency Initiative
The ISPOR Real-World Evidence (RWE) Transparency Initiative moves forward towards the Society’s goals while underscoring the need for transparency in [...]
[ebook] Version 4.1 of the AMCP Format: Product Dossiers
On December 23, 2019, the Academy of Managed Care Pharmacy (AMCP) released Version 4.1 of the AMCP Format for Formulary [...]